Cullinan Therapeutics, Inc. (CGEM)
收市後：
- Benzinga
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in au
- Benzinga
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
Cullinan Therapeutics Inc (NASDAQ:CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication. In SLE, the immune system of the body mistakenly attacks healthy tissue. The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated
- Insider Monkey
13 Best Booming Stocks to Buy Right Now
In this article, we will take a detailed look at the 13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now. Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market […]
